WO1986000016A1 - Traitement de l'herpes simplex - Google Patents

Traitement de l'herpes simplex Download PDF

Info

Publication number
WO1986000016A1
WO1986000016A1 PCT/US1984/000920 US8400920W WO8600016A1 WO 1986000016 A1 WO1986000016 A1 WO 1986000016A1 US 8400920 W US8400920 W US 8400920W WO 8600016 A1 WO8600016 A1 WO 8600016A1
Authority
WO
WIPO (PCT)
Prior art keywords
bis
phenol
diacetate
ester
dosage
Prior art date
Application number
PCT/US1984/000920
Other languages
English (en)
Inventor
Gerald N. Kern
Original Assignee
Medical Technology Corp. Of America, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Technology Corp. Of America, Inc. filed Critical Medical Technology Corp. Of America, Inc.
Priority to JP59502497A priority Critical patent/JPS61502395A/ja
Priority to EP19840902564 priority patent/EP0183694A4/fr
Priority to PCT/US1984/000920 priority patent/WO1986000016A1/fr
Publication of WO1986000016A1 publication Critical patent/WO1986000016A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

  • Herpes Simplex Herpesvirus Hominis
  • Herpes Simplex occurs in two antigenic tyes. Herpes febrilis and Herpes genitalis, referred as Type 1 and Type 2. Infection is usually manifested by the appearance of vesicular eruptions, oral herpetic lesions, commonly referred to as fever blisters, or cold sores about the lips in the instance of Herpes Simplex Type 1, and vesicular lesions on and about the male or female genitalia in the instance of Herpes Simplex Type 2.
  • Persons with Herpes Simplex infections are likely to have recurrent periods of lesion development spaced by periods of remission. Management of the condition involves easing the itching sensation which accompanies the lesion periods, and speeding remission.
  • (p-hydroxyphenyl) phthalide in amounts up to 100 milligrams, preferably 15 to 30 milligrams initially and repetitively at predetermined intervals. Because 3,3-bis (p-hydroxyphenyl) phthalide is a cathartic, there is an unpleasant side effect to its use which suggests reduced usage concentrations, but the patentee does not suggest any lower dosage will be effective in Herpes Simplex management. Summary of the Invention
  • Still other objects include provision of products comprising phenol, 4,4'- (2-pyridinyl methylene) bis diacetate (ester), carriers and therapeutic agents for coapplication with phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester).
  • the method includes administering such dosage orally, administering a dosage of from about 0.1 to about 9.5 milligrams of phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), suspending the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) in a carrier for administration, combining the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) with a second therapeutic agent in an effective dosage for administration therewith, e.g.
  • the invention further contemplates provision of a product comprising a dosage of phenol, 4,4'- (2-pyridinyl methylene) bis,- diacetate (ester) effective upon oral ingestion for management of Herpes Simplex, and less than is effective for catharsis of the person receiving the dosage and combined with an ingestible carrier.
  • the product comprises a dosage between 0.1 and 9.5 milligrams, and may further comprise one or more vitamins in effective dosage, preferably free of an enteric coating.
  • Phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), commonly referred to as Bisacodyl is a diphenyl trimethane suitably prepared from 2-pyridine- carboxaldehyde condensed with phenol in the presence of sulfuric acid or other dehydrant, followed by esterification with acetic anhydride and anhydrous sodium acetate, as described in U.S.P. 2,764,590. It is a white to off-white crystalline powder slightly soluble in water but fairly soluble in common organic solvents. It is known to be used as a contact laxative, acting to increase peristalsis throughout the large intestine.
  • a typical dose as a laxative is oral or rectal not less than 10 milligrams and up to 30 milligrams and is administered in an enteric coating to ensure passage to the larage intestine. It is known to inhibit glucose absorption and intestinal Na-K-ATPase activity.
  • the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) may be combined with other therapeutic agents each for its own purpose e.g. to relieve stress, or to enhance the effectiveness of the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) when administered.
  • agents as vitamins A, D, E, C, Folic acid, B-l, B-2, Niacin, B-6, and B-12, among others can be combined with the phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester).
  • agents for combining with phenol, 4,4'- ⁇ 2-pyridinyl methylene) bis diacetate (ester) include amino acids, such as lysine and leucine; proteins such as gelatin and gliadin; or carbohydrates, e.g. starch, lactose and the like.
  • the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) may be suitably dispersed in a carrier, e.g. tablet or capsule carriers and components such as excipients, bulking agents, lubricants, disintegrants, dyes and the like as are known in tablet making technology for the purpose of easing the administration of the phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester).
  • carrier further embraces vehicles used or useful in preparing injection form of the phenol, 4,4 ⁇ -(2-pyridinyl methylene) bis,- diacetate (ester) products of the invention, such as sesame oil and the like.
  • OMPI capsule 3.35 milligrams of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) with 490 milligrams of an aliquot of a mixture of vitamins comprising:
  • Vitamin A 2500 units Vitamin D 400 units Vitamin E 15 units Vitamin C 60 mg. Folic acid 0.3 mg. Vitamin B-l 1.0 mg. Vitamin B-2 1.2 mg. Niacin 13.5 mg. Vitamin B-6 1.0 mg. Vitamin B-12 4.5 mg. blended with 2 parts of cornstarch per part of vitamin mix.
  • the effective dosage rate for the CONTROL I and II treatments was 30 milligrams per 8 hours for the first day, and a like amount at 12 hour intervals
  • the EXAMPLE I dosage rate was one capsule (3.35 mg. per dosage) every six to eight hours on the first day and thereafter at 8 to 12 hour intervals.
  • vitamins in the EXAMPLE I formulation adds stress relief factors to the formulation to ameliorate the stress which often accompanies onset of a Herpes condition.
  • a second capsule formula of the invention composition was prepared from: phenol, 4,4*-(2-pyridinyl methylene) bis diacetate (ester) 3 . 5 mg . phenacetin 350. mg . chloropheniramine maleate 3. mg . caffein 38. mg . phenylpropanolamine HCL 9. mg . by blending the ingredients eutectically.
  • a tablet form of the invention dosage is prepared by blending phenol, 4,4 • -(2-pyridinyl methylene) bis diacetate (ester), 3.5 mg. , 100 mg. lactose, 100 mg. starch, and 10 mg. talc as a lubricant. It will be noted that this formulation can be packaged in capsule form with the omission of the talc and adjusting the lactose and starch concentration accordingly.
  • a protein containing capsule is prepared by blending eutectically phenol, 4,4'-(2- ⁇ yridinyl methylene) bis diacetate (ester), 3.5 mg. , 200 mg. lactose, 100 mg. gliadin or gelatin protein, and about 100 mg. of the amino acid lysine.
  • An intramuscular injectable formulation is prepared by blending, per dosage, 5 cc. sesame oil, 250 units of Vitamin E, and 5 mg. of phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un procédé pour traiter efficacement l'herpes simplex comprend l'administration d'une dose efficace de phénol, 4,4'-(2-pyridinyl méthylène) bis diacétate (ester), en combinaison avec un porteur, des vitamines ou d'autres agents thérapeutiques; le produit administré en dose efficace pour mettre en oeuvre le procédé comprend du phénol, 4,4'-(2-pyridinyl méthylène) bis diacétate (ester).
PCT/US1984/000920 1984-06-11 1984-06-11 Traitement de l'herpes simplex WO1986000016A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP59502497A JPS61502395A (ja) 1984-06-11 1984-06-11 単純ヘルパスの治療
EP19840902564 EP0183694A4 (fr) 1984-06-11 1984-06-11 Traitement de l'herpes simplex.
PCT/US1984/000920 WO1986000016A1 (fr) 1984-06-11 1984-06-11 Traitement de l'herpes simplex

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1984/000920 WO1986000016A1 (fr) 1984-06-11 1984-06-11 Traitement de l'herpes simplex

Publications (1)

Publication Number Publication Date
WO1986000016A1 true WO1986000016A1 (fr) 1986-01-03

Family

ID=22182169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1984/000920 WO1986000016A1 (fr) 1984-06-11 1984-06-11 Traitement de l'herpes simplex

Country Status (3)

Country Link
EP (1) EP0183694A4 (fr)
JP (1) JPS61502395A (fr)
WO (1) WO1986000016A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2764590A (en) * 1952-03-17 1956-09-25 Thomae Gmbh Dr K Certain 4, 4'-disubstituted-diphenylpyridyl methanes and process
US2827465A (en) * 1958-03-18 Process of preparation of x
US3526635A (en) * 1968-12-03 1970-09-01 Synergistics Magnesium complex of dihydroxydiphenyl-isatin,4,4-dehydroxydiphenyl (2-pyridyl) methane,4,4'-dihydroxydiphenyl-2' - (aminophenyl methane) and phenophthalein
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2827465A (en) * 1958-03-18 Process of preparation of x
US2764590A (en) * 1952-03-17 1956-09-25 Thomae Gmbh Dr K Certain 4, 4'-disubstituted-diphenylpyridyl methanes and process
US3526635A (en) * 1968-12-03 1970-09-01 Synergistics Magnesium complex of dihydroxydiphenyl-isatin,4,4-dehydroxydiphenyl (2-pyridyl) methane,4,4'-dihydroxydiphenyl-2' - (aminophenyl methane) and phenophthalein
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 88, No. 9, issued 27 February 1978 (Columbus, Ohio, USA), OHNUMA et al., Intestinal Absorption of Sodium Picosulfate and Bisacodyl 88:58209g (1978) *
CHEMICAl ABSTRACTS, Vol. 92, No. 5, issued 4 February 1980 (Columbus, Ohio, USA), STEINBACH et al., Studies Under Dosage Precision of Bisacodyl in Oral Laxatives 92:47265 (1980) *
See also references of EP0183694A4 *

Also Published As

Publication number Publication date
JPS61502395A (ja) 1986-10-23
EP0183694A4 (fr) 1987-06-16
EP0183694A1 (fr) 1986-06-11

Similar Documents

Publication Publication Date Title
US4588744A (en) Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide
US4654373A (en) Pharmaceutical formulations containing coenzyme Q10 suitable for topic administration
US4256763A (en) Treatment of herpes simplex infections and acne
JPH03181422A (ja) 炎症の治療方法及び炎症の治療用合成薬
JPH1036269A (ja) 月経困難症及び／又は月経前症候群の軽減用薬剤
Yoovathaworn et al. Influence of caffeine on aspirin pharmacokinetics
US4810707A (en) Herpes simplex treatment
US3560612A (en) Method of alleviating hypercitricemia
WO1999026613A1 (fr) Compositions a base d'aminoguanidine destinees au traitement de dermatoses proliferantes
US3928609A (en) Non-alcoholic theophylline product
US4438129A (en) Use of clotrimazole to treat herpes labialis
US4520132A (en) Use of undecylenic acid to treat herpes labialis
JPH03503177A (ja) 皮膚の疾患の局所的処置のためのサイモペンチンを含有する組成物
CA1261269A (fr) Traitement de l'herpes simplex
WO1986000016A1 (fr) Traitement de l'herpes simplex
CA1207238A (fr) Utilisation de l'haloprogine dans le traitement de l'herpes des levres
Mobacken et al. Ketoconazole treatment of 13 patients with chronic mucocutaneous candidiasis: A prospective 3-year trial
JP3657285B2 (ja) 皮膚外用組成物
US4105794A (en) Process of mitigating cholelithiasis
USRE32990E (en) Use of undercylenic acid to treat herpes labialis
EP0073758B1 (fr) Traitement des infections virales inflammatoires, de l'acne, des dermatites et de l'arthrite
US4438134A (en) Use of tolnaftate to treat herpes labialis
US4959369A (en) Synergistic combinations
US4537908A (en) Herpes II treatment
Shuster Comparative trial of two non-sedative H1 antihistamines, terfenadine and astemizole, for hay fever.

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU JP

Kind code of ref document: A1

Designated state(s): AU JP

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB LU NL SE

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1984902564

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1984902564

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1984902564

Country of ref document: EP